Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Otlertuzumab |
| Trade Name | |
| Synonyms | TRU-016|TRU016|TRU 016 |
| Drug Descriptions |
Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057). |
| DrugClasses | CD37 Antibody 9 |
| CAS Registry Number | 1372645-37-8 |
| NCIT ID | C74006 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bendamustine + Otlertuzumab | Bendamustine Otlertuzumab | 0 | 1 |
| Ibrutinib + Otlertuzumab | Ibrutinib Otlertuzumab | 0 | 1 |
| Idelalisib + Otlertuzumab + Rituximab | Idelalisib Otlertuzumab Rituximab | 0 | 1 |
| Obinutuzumab + Otlertuzumab | Obinutuzumab Otlertuzumab | 0 | 1 |
| Otlertuzumab | Otlertuzumab | 0 | 0 |
| Otlertuzumab + Rituximab | Otlertuzumab Rituximab | 0 | 1 |